Ï ÏõñáíïêáôÝâáôïò åîïìïëïãåßôáé...

Boy Ðñéí 2 åâäïìÜäåò åß÷á ôá ãåíåèëéÜ ìïõ.

Ôçí ðáñáìïíÞ ôùí ãåíåèëßùí ìïõ åß÷á ðñïãñáììáôßóåé ìéá ìéêñïåðÝìâáóç ñïõôßíáò. Ôçí ðáñáìïíÞ áõôÞò ôçò åðÝìâáóçò åß÷á ðÜåé íá äþóù áßìá ãéá ðñïåã÷åéñçôéêü Ýëåã÷ï.

ÊáèéóìÝíïò óôïí ÷þñï áíáìïíÞò ÷åéñïõñãçèÝíôùí, Þñèå ï ãéáôñüò ìå áðüëõôç øõ÷ñáéìßá êáé ìïõ åßðå îåñÜ ðùò âãÞêá èåôéêüò.

Åêåßíç ôçí þñá Ýöõãå ç ãç êÜôù áðï ôá ðüäéá ìïõ.
MåôÜ áðï ëßãï ìßóçóá ôï ðåôóß ìïõ. Äåí Ýíéùèá ôï óþìá ìïõ, äåí ìðïñïýóá íá ôï ðéóôÝøù. Óôï ôÝëïò Üñ÷éóá íá êëáßù.
Ôï êáëýôåñï êïììÜôé ôçò ìÝñáò Þôáí ç áíáéóèçóßá ðïõ ìïõ êÜíáí.

Ôïí Ìáßï ôïõ 2009 åß÷á Ýíá áôý÷çìá ìå ìéá ãíùñéìßá, áðï áõôÝò ðïõ Ýñ÷ïíôáé êáé ðåñíÜíå.
ÈÝëù íá ðéóôåýù ïôé ïýôå áõôüò Þîåñå, ãéáôé ôïí ñþôçóá ìüëéò áíôéëçöèçêá ôï óõìâÜí.

¸êëáøá ðïëý, ü÷é ãéá ìÝíá, åìÝíá äåí ìå íïéÜæåé êé áí öýãù áýñéï, ïýôùò ç Üëëùò ç æùç äåí ìïõ Ý÷åé öåñèåß êáëÜ, ìéá áêüìá ðßêñá äåí åßíáé êÜôé.
ËõðÞèçêá ãéá ôçí ìÜíá ìïõ, ðïõ ïñöÜíåøå, ðïõ êüíôåøå íá ÷Üóåé ðáéäß êáé ôþñá áõôü.
ËõðÞèçêá ãéá ôïí ðáôÝñá ìïõ, ðïõ ôïí êåñíÜù ðÜëé ðßêñá.
ËõðÞèçêá ãéá ôïí Üíèñùðï ðïõ åß÷á áñ÷ßóåé íá åñùôåýïìáé åðéöõëáêôéêÜ.

Åßìáé áðï ôïõò áíèñþðïõò ðïõ ðéóôåýïõí ïôé ôï ãéáôñéêü áõôïý ôïõ êüóìïõ åßíáé ç åéëéêñßíåéá.
¼óï ìïõäéáóìÝíïò êé áí Þìïõí, üóï ëßãç êé áí Þôáí ç åðáöÞ ìïõ ìå ôçí ðñáãìáôéêüôçôá åêåßíç ôçí åâäïìÜäá, âñÞêá ôï èÜññïò íá ôï áíáêïéíþóù óå ößëïõò, óõããåíåßò êáé ïéêïãÝíåéá.
ÐñáãìáôéêÜ óõãêëïíßóôçêá ìå ôçí óôçñéîÞ ôïõò. Ãéá íá åßìáé åéëéêñéíÞò ðåñßìåíá íá ìå áíôéìåôùðßóïõí äéóôáêôéêÜ Þ óáí ëÝðñï.

Äåí ìðïñïýóá íá êïéìçèþ ôá âñÜäéá.
¹ìïõí áã÷ùìÝíïò êáé ðßóôåõá óå Ýíá èáýìá, ðåñßìåíá íá âãïõí ïé åðáíáëçðôéêÝò, ðåñßìåíá íá åßíáé üëá Ýíá ëÜèïò, íá åêôéìÞóù üëá áõôÜ ðïõ êéíäõíåýù íá ÷Üóù.

ÌÝóá óôéò åðüìåíåò ìÝñåò Ýðñåðå íá ôï ðù êáé óôïí åñùìÝíï ìïõ. Ðáñüëï ðïõ äåí åß÷á êáìßá õðï÷ñÝùóç, äéüôé ç ó÷Ýóç ìáò Þôáí êÜôé áóáöÝò.
¹ôáí ìéá åðáöÞ ðïõ îåêßíçóå ùò óùìáôéêÞ êéíÞèçêå åëáöñþò óôá ðëáßóéá ôçò öéëßáò áëëá ÷ùñßò ðåñéèþñéá ãéá êáôé ïõóéáóôéêü.
Åãþ áõôüí ôïí Üíèñùðï ôïí Þèåëá ðïëý êé åðåéäÞ åáí åîáöáíéæüìïõí Ýôóé èá ôï êáôáëÜâáéíå ïôé êÜôé ôñÝ÷åé, áðïöÜóéóá íá åßìáé åéëéêñéíÞò ìáæß ôïõ, üðùò Þôáí êé áõôüò áðåíáíôß ìïõ êáè’ïëç ôçí äéÜñêåéá ôçò ãíùñéìßáò, áêüìá êé áí áõôüò äåí Þèåëå íá åßíáé ï éäáíéêüò ãéá ìÝíá.

Óôï áìÜîé ðïõ ïäçãïýóá êáé ôïõ ôï áíáêïßíùóá, áõôüò Ýâáëå ôá êëÜììáôá, ìåãÜëïò Üíôñáò, íá êëáßåé óáí ðáéäß, êé ýóôåñá ìïõ åßðå «óå áãáðþ».
Ôéò ëÝîåéò ðïõ äå îåóôüìéóå êáíåßò áðï áõôïýò ðïõ 9 ÷ñüíéá ìïõ ôÜæáí ëáãïýò ìå ðåôñá÷åßëéá êáôá ðåñéüäïõò, ôéò îåóôüìéóå áõôüò, ðïõ óôçí ôåëéêÞ ãé áõôüí Üíåôá èá ìðïñïýóá íá åßìáé áðëÜ Ýíá óêåýïò çäïíÞò.
Ôá åðüìåíá äåõôåñüëåðôá Ýðáèá blackout êáé ôñÜêáñá.

¸÷ïõíå ðåñÜóåé 2 âäïìÜäåò Ýêôïôå, áêüìá ðåñéìÝíù ôéò åîåôÜóåéò ãéá ôï ééêü öïñôßï.
¸÷ù îáíáìðåß óôçí ñïõôßíá ìïõ, êïéìÜìáé ôá âñÜäéá, êé áõôüò ï Üíèñùðïò åßíáé äßðëá ìïõ ÷ùñßò íá Ý÷ïõìå ïñßóåé ôé åßìáóôå, áëëá ôé íá ëÝåé? Ôïí åêôéìþ ãé áõôü.
Äåí îÝñù áí ç áãÜðç ôá õðåñíéêÜ üëá, ðñïöáíþò ç ýðáñîç ôçò êïéíÞò ìáò óåîïõáëéêÞò æùÞò ðñïûðïèÝôåé íá ñéóêÜñåé, Ýóôù êáé áõôü ôï ëßãï, ìå ôï ðñïöõëáêôéêü, áëëá äåí ìðïñþ íá ôïí âÜëù óå áõôÞí ôçí äéáäéêáóßá.
Ç áãÜðç ßóùò åßíáé õðåñôéìçìÝíç.
Äå îÝñù ðùò èá êéíçèåß ç æùÞ ìïõ áðï äù êáé ðÝñá.

Äõóôõ÷þò áðï äù êáé ðÝñá ïé åðéëïãÝò ìïõ åßíáé áêüìá ðéï ðåñéïñéóìÝíåò, èá ðñÝðåé íá öïâÜìáé êáé ôçí ðéï áðëÞ êßíçóç, üðùò íá ìïõ ðñïóöÝñåé êÜðïéïò Ýíá ëïõëïýäé êé åãþ íá ðñïóÝ÷ù ôï áãêÜèé.

Êáëü êïõñÜãéï óå üëïõò.

ÏõñáíïêáôÝâáôïò




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò